Automation in the Molecular Diagnostics Market by Type, Application, End-use

Description

List of Tables

[193 Pages Report] The Automation in the Molecular Diagnostics Market size was estimated at USD 11.75 billion in 2023 and expected to reach USD 13.54 billion in 2024, at a CAGR 15.79% to reach USD 32.81 billion by 2030.

Automation in molecular diagnostics refers to the use of advanced technologies and machinery to perform complex laboratory tests that detect and measure the presence of genetic materials, including DNA and RNA, in a patient's sample, including blood, saliva, and tissue. Unlike traditional methods that require significant manual effort and time, automation streamlines these processes, making them faster, more accurate, and capable of handling a large volume of tests simultaneously. The rising focus on personalized healthcare and precision medicine necessitates more efficient and accurate diagnostics. Moreover, the increasing incidence of chronic diseases worldwide boosts the demand for automated molecular diagnostics. Various government programs and funding in healthcare infrastructure and research encourage the adoption of these technologies. However, the initial investment in automation technology can be prohibitive for smaller labs and institutions. Furthermore, continuous innovations in automation technology, such as high-throughput systems and AI integration, drive the market forward. Integrating AI and machine learning to enhance data analysis and interpretation in diagnostics poses significant opportunities for manufacturers.

KEY MARKET STATISTICS
Base Year [2023]	USD 11.75 billion
Estimated Year [2024]	USD 13.54 billion
Forecast Year [2030]	USD 32.81 billion
CAGR (%)	15.79%

Type: Increasing significance of amplification automation in high-throughput settings

Amplification automation pertains to the process of amplifying & making multiple copies of the genetic material (DNA or RNA) to detectable levels. It is a crucial step in molecular diagnostics for identifying pathogens and genetic mutations and for any application requiring a significant quantity of genetic material for analysis. Amplification automation is particularly indispensable in high-throughput settings where a large number of samples need consistent and rapid processing, such as in infectious disease outbreaks or large-scale genetic testing. The automation segment of analysis involves the automated interpretation of amplified genetic material. This includes software-based analysis for variant detection, quantification, and mutation identification. Analysis automation is essential for laboratories aiming to minimize human error in data interpretation and those that require fast turnaround times without compromising accuracy. Extraction automation refers to the process of automatically extracting nucleic acids (DNA/RNA) from samples, which is the first step in most molecular diagnostic protocols. This type of automation ensures high purity and yield of nucleic acids, which is crucial for the success of subsequent diagnostic steps. Post-analytical automation involves the automated management of data post-analysis, including report generation, data storage, and result dissemination. This ensures accurate and timely communication of diagnostic results. Pre-analytical automation includes sample labeling, sorting, and preparation before the actual diagnostic tests are performed. This phase is essential for reducing pre-analytical errors and enhancing the overall efficiency of the diagnostic process.

End-use: Research institutions prefer highly customizable and scalable automation solutions

Clinical laboratories prioritize high throughput and accuracy with minimal error rates. Automation allows for the processing of a large volume of tests with consistent results, which is crucial in high-demand environments. These laboratories typically have a broader range of testing portfolios and require automation flexibility to handle various types of assays and samples. Hospitals require automation solutions that support rapid turnaround times and are easy to integrate into their existing hospital information systems. The focus is on point-of-care testing and the ability to quickly adapt to varied testing demands, including emergency and routine diagnostic tests. Research institutions have a distinct need for automation in molecular diagnostics, emphasizing flexibility, scalability, and precision. These establishments are focused on experimental research, requiring equipment that can accurately handle a wide variety of assays and experimental conditions.

Regional Insights

The United States and Canada are leading in the Americas region due to their advanced healthcare infrastructure, significant investment in research & development, and high healthcare expenditure per capita. The demand in these countries is accelerated by the need for quicker and more accurate diagnostic tests for a variety of diseases, including infectious diseases, cancer, and genetic disorders. There is a high emphasis on the integration of data management systems with diagnostic equipment to streamline workflows and improve patient outcomes. The European Union countries show a strong trend towards adopting automated molecular diagnostics, driven by the availability of healthcare funding, stringent regulatory standards, and a high degree of awareness about advanced diagnostic solutions. Initiatives such as the EU's Horizon 2020 have supported research and innovation in healthcare, including molecular diagnostics, leading to the development of new technologies and systems. The Middle East is experiencing growth in adopting advanced healthcare technologies due to substantial healthcare investments in countries including Saudi Arabia & UAE. The APAC region, encompassing countries including China, Japan, and India, has shown remarkable growth in the adoption of automated molecular diagnostics. The growth is primarily driven by rising healthcare expenditure and, awareness about early disease detection, and government initiatives towards healthcare improvement.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Automation in the Molecular Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Automation in the Molecular Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Automation in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaltis S.r.l., altona Diagnostics GmbH, AstraGene, Becton, Dickinson and Company, Biocartis, bioMerieux S.A., Danaher Corporation, ELITech Group, F. Hoffmann-La Roche Ltd., Hologic, Inc., MEGAROBO technologies Co., Ltd., Meridian Bioscience, Molecular Devices, LLC, Mylab Discovery Solutions, QIAGEN N.V., QuidelOrtho Corporation, Revvity, Inc., Sansure Biotech Inc., Scispot.io Inc., Seegene, Inc., Siemens Healthineers AG, Tecan Group Ltd., The Festo Group, and Vela Diagnostics.

Market Segmentation & Coverage

This research report categorizes the Automation in the Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Amplification Automation
- Analysis Automation
- Extraction Automation
- Post-analytical Automation
- Pre-analytical Automation

Application
- Blood Screening
- Genetic Testing
- Infectious Diseases
- Oncology

End-use
- Clinical Laboratories
- Hospitals
- Research Institutions

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Automation in the Molecular Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Automation in the Molecular Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Automation in the Molecular Diagnostics Market?

4. What is the market share of the leading vendors in the Automation in the Molecular Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Automation in the Molecular Diagnostics Market?

Product Code: MRR-2D1F5C65740B

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising focus on personalized healthcare and precision medicine
  - 5.1.1.2. Increasing incidence of chronic diseases across the globe
  - 5.1.1.3. Upsurge in the need for point of care diagnostics
- 5.1.2. Restraints
  - 5.1.2.1. High initial investment associated with automation technology
- 5.1.3. Opportunities
  - 5.1.3.1. Continuous innovations in automation technology including high-throughput systems and AI integration
  - 5.1.3.2. Government programs and funding in healthcare infrastructure and research
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations associated with the approval process
5.2. Market Segmentation Analysis
- 5.2.1. Type: Increasing significance of amplification automation in high-throughput settings
- 5.2.2. End-use: Research institutions prefer highly customizable and scalable automation solutions
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Automation in the Molecular Diagnostics Market, by Type

6.1. Introduction
6.2. Amplification Automation
6.3. Analysis Automation
6.4. Extraction Automation
6.5. Post-analytical Automation
6.6. Pre-analytical Automation

7. Automation in the Molecular Diagnostics Market, by Application

7.1. Introduction
7.2. Blood Screening
7.3. Genetic Testing
7.4. Infectious Diseases
7.5. Oncology

8. Automation in the Molecular Diagnostics Market, by End-use

8.1. Introduction
8.2. Clinical Laboratories
8.3. Hospitals
8.4. Research Institutions

9. Americas Automation in the Molecular Diagnostics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Automation in the Molecular Diagnostics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Automation in the Molecular Diagnostics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Biocare Medical and Molecular Instruments Join Forces to Elevate Bioimaging Technologies
- 12.3.2. The Launch of BugCount Guardian by LuminUltra to Enhnace Industrial Microbial Monitoring
- 12.3.3. Yourgene Health Unveils Revolutionary MagBench Technology for Enhanced Non-Invasive Prenatal Testing
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio